About this item:

335 Views | 207 Downloads

Author Notes:

Meghan Delaney, DO, MPH, Bloodworks NW, 921 Terry Avenue, Seattle, WA 98104; meghand@bloodworksnw.org.

We thank Sarah Galdzicka for her assistance with the study.

The authors have disclosed no conflicts of interest.

Subjects:

Research Funding:

Funded by the Academic Enrichment Fund, Seattle Children’s Hospital; Catherine Holmes Wilkins Foundation (Seattle, WA); Faculty Research Support Fund, Seattle Children’s Hospital, Center for Clinical & Translational Research, CTSA Grant UL1TR000423.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • BLOOD-DONORS
  • NEWBORN-INFANTS
  • TRANSMISSION
  • PREVENTION
  • METAANALYSIS
  • PRODUCTS

Postnatal cytomegalovirus infection: a pilot comparative effectiveness study of transfusion safety using leukoreduced-only transfusion strategy

Tools:

Journal Title:

Transfusion

Volume:

Volume 56, Number 8

Publisher:

, Pages 1945-1950

Type of Work:

Article | Post-print: After Peer Review

Abstract:

The optimal mitigation strategy to prevent transfusion transmission of cytomegalovirus (TT-CMV) in preterm very low birthweight infants remains debated. Hospitals caring for this patient population have varied practices. STUDY DESIGN AND METHODS: A prospective observational comparative effectiveness pilot study was conducted to determine the feasibility for a larger study. The pilot was carried out at hospitals using a leukoreduction (LR)-only transfusion strategy. Specimen and data collection for this study was performed in a similar approach to a study completed at Emory University that employed the CMV-seronegative plus LR approach. All testing was performed at one laboratory. The rates of TT-CMV using the two transfusion strategies were compared. RESULTS: Zero incidence of TT-CMV was detected in infants (n = 20) transfused with LR-only blood (0/8; 95% confidence interval [CI], 0-25.3%) and is consistent with the previously reported zero incidence of TT-CMV finding in a cohort of infants transfused with CMV-negative plus LR blood (0/310; 95% CI, 0%-0.9%). The seroprevalence rate among enrolled mothers (n = 17) was 60%. Forty percent of those infants (8/20) received 43 transfusions; five were transfused with one or more CMV-seropositive blood components. One infant had tested positive for CMV before receiving blood transfusions; the infant's mother was CMV immunoglobulin (Ig)G positive and IgM negative. CONCLUSIONS: Using the LR-only transfusion approach, zero cases of TT-CMV were detected in this pilot study. A larger study is needed to reliably determine the most effective strategy for prevention of TT-CMV in this population.

Copyright information:

© 2016 AABB

Export to EndNote